D
ata from the CAPRISA 004 trial provides further insights into a potential correlate of protection against HIV infection. This case control study, which was published this week in the Journal of AIDS, showed that a tenofovir concentration of 100 ng/mL in cervicovaginal fluid (CVF) was associated with 65% (95% CI: 6% to 87%) protection against HIV, whereas a 1000 ng/mL concentration correlated with 76% (95% CI: 8% to 92%) protection against HIV infection.
The CA-PRISA 004 trial showed that coitally dosed tenofovir 1% gel reduced HIV acquisition by 39% overall and 54% when used consistently. The objective of this analysis was to ascertain its pharmacokinetic-pharmacodynamic relationship to protect against HIV acquisition.
Genital and systemic tenofovir concentrations in 34 women who acquired HIV (cases) were compared with 302 randomly selected women who remained HIV uninfected (controls) during the CAPRISA 004 trial. In total, 336 CVF, 55 plasma, and 23 paired cervical and vaginal tissue samples were assayed by validated methods for tenofovir and tenofovir diphosphate (tenofovir-DP) detection.
Tenofovir was detected in the genital tract in 8 (23.5%) cases and 119 (39.4%) controls (P = 0.076). Among those with detectable genital tract tenofovir, the median CVF concentrations were 97% lower in cases compared with controls, 476 versus 13,821 ng/mL (P = 0.107). A total of 14.7% (5/34) of cases and 32.8% (99/302) of controls were found to have tenofovir CVF concentrations above 100 ng/mL [odds ratio (OR): 0.35, P = 0.037] (Figure) .
At a higher threshold, 8.8% (3/34) of cases and 26.2% (79/302) of controls were found to have tenofovir CVF concentrations above 1000 ng/mL (OR: 0.27, P = 0.036). Plasma tenofovir concentrations were ,1 ng/mL in all women and were detected only in controls (16.7%) and not in cases (0%), (P = 0.031). Returned used tenofovir gel applicators and CVF concentrations were correlated (Spearman r = 0.22, P = 0.001).
Based on this analysis, the attainment of this concentration during sexual exposure consistently may be necessary to achieve high levels of protection against HIV. This multi-institutional team has been awarded three years of funding for a systems immunology project that aims to identify and validate correlates of risk of TB disease, treatment success or recurrent TB disease, and to improve understanding on the biology of TB pathogenesis from latent to active TB disease. The project is leveraging new opportunities for biomarker discovery and validation from a number of completed and currently active clinical studies in South Africa. Valuable specimens from HIV-uninfected or HIV-infected persons at risk of TB disease, those who have been diagnosed with TB and are on TB treatment or who are at risk of recurrent TB have been or are being analysed in various sub-studies to address the project objectives.
The group reviewed early project results, deliberated about the proposed next steps and approaches and much discussion revolved around how best to account for degree of immunocompromise in case/control matching in HIV-infected populations. A number of very exciting scientific questions are being addressed that enhance our knowledge of TB immunopathogenesis and inform development of new tests for TB diagnosis, predicting incident TB, monitoring TB treatment and predicting recurrent TB. In conversation with the Director L aunched in May this year the CAPRISA Tea Talks initiative has created an opportunity for employees to engage on a personal level or in groups with the Director ,Professor Salim Abdool Karim. Conversations range from seeking advice regarding careers, future scientific studies or advice for their children's career. Employees have welcomed the initiative which is held at all the CAPRISA research sites. "It is not a forum for confidential discussions as staff can meet with the Director at his offices for these discussions," explained Ms Marietjie Geldenhuys Manager of Human Resources at CA-PRISA. She said that the initiative is extremely successful and it is "unique to have the Director create opportunities to interact in an informal setting and encourage meaningful conversations". 
Hosting the MRC SHIP TB biomarker meeting

Staff at the Vulindlela Clinical Research site who participated in the Tea
CAPRISA participates in Harvard's Transmed course
D
r Kogie Naidoo hosted medical students from the Ragon Institute at Harvard and participated in the Transmed course organised by Harvard's Ragon Institute. As part of scientific capacity building in Africa, three students from South Africa, one from CAPRISA and two from the HPP, and one from Zimbabwe received support from the Ragon Institute to attend the course.
Dr Fillipos Porichis Director of International Programs, Ragon Institute of MGH, MIT and Harvard who led the delegation explained that the main goal of the course 'was to educate students on how to identify unmet medical needs and how to employ translational solutions'. He said that the visit to the CAPRISA research clinic provided students 'with a unique opportunity to identify the unmet medical needs of HIV and/or TB infections and through the different talks, the students were able to see firsthand the design, execution and analysis of clinical trials addressing some of the medical needs that were identified'.
The visit and participation at the CAPRISA ECRS was significant as it contributed to the development of the curriculum said Dr Kogie Naidoo. "This course is a great example of collaborative efforts in finding innovative solutions to unmet medical needs that contribute daily to unnecessary suffering and death. I was struck by the interest and motivation in the group in accessing first world technologies to find novel interventions for the scourge of HIV and TB." 
